Alport syndrome in patient who was diagnosed as thin basement membrane nephropathy previously
분야
의약학 > 내과학
저자
( Nam Jun Cho ) , ( La Young Yoon ) , ( Min Jin Kim ) , ( Eun Jung Kim ) , ( Moo Yong Park )
발행기관
대한내과학회
간행물정보
대한내과학회 추계학술발표논문집 2011년, 제2011권 제1호, 259(총1쪽)
파일형식
42846669.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    TBMN occurs in at least 1% of the population and has been known benign disease. But in recent reports, some doctors presented that TBMN had progressive course. We experience Alport syndrome in 19-year old male patient who was diagnosed as TBMN 6 years ago. At that time, urine analysis revealed proteinuria (2155 mg/day) with 10~29RBCs/HPF. After diagnosis, he lost of follow up. During loss of follow up period, he had progressive nephritis with prominent proteinuria(2402 mg/day), declining renal function(BUN 30.1 mg/dL, creatinine 2.7 mg/dL, glomerular filtration rate of 18.2mL/min by Tc99m DTPA renal scan), sensorineural hearing loss and recurrent corneal erosion. We performed repeat renal biopsy and the result of second biopsy was consistent with Alport syndrome. He was managed conservatively with ARB(Telmisartan) and prednisolone. After 3 month, TP/Cr ratio of spot urine decline from 3549 mg/dL to 478 mg/dL and creatinine level mild improved to 2.2 mg/dL. In conclusion, we recommend clinicians should exercise caution and observe the course of disease when patients had prominent proteinuria, familial history and other extra-renal manifestations, even if TBMD.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.